Clinical trials: Advanced Non-squamous Non-Small-Cell Lung Cancer
Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of etrumadenant (AB928) in combination with…
- Conditions
- Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer
- Trial name
- NCT03629756
- Testing
- Etrumadenant, Zimberelimab
- Where
- 15 sites in United States, Australia
- Volunteers
- 48 people
- Sponsor
- Arcus Biosciences, Inc.
Non-Small Cell Lung Cancer
A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
This is a multicenter, randomized, open-label, controlled phase III clinical study to evaluate the efficacy and safety of HS-20093 injection combined with adebrelimab versus docetaxel in previously treated patients with advanced…
- Trial name
- NCT07464327
- Testing
- HS-20093, Docetaxel
- Volunteers
- 450 people
- Sponsor
- Hansoh BioMedical R&D Company
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas.
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma
- Trial name
- NCT05565417
- Testing
- IMT-009, Fruquintinib
- Where
- 9 sites in United States
- Volunteers
- 67 people
- Sponsor
- Immunitas Therapeutics
Lung Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006378
- Testing
- carboplatin, paclitaxel, radiation therapy
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Case Comprehensive Cancer Center
Lung Cancer, Non-squamous, Non-small Cell
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including…
- Trial name
- NCT06151574
- Testing
- zongertinib, pembrolizumab, cisplatin
- Where
- 163 sites in United States, Argentina and 24 more
- Volunteers
- 428 people
- Sponsor
- Boehringer Ingelheim
Advanced Non Small Cell Lung Cancer (NSCLC)
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
The purpose of this study was to determine if AUY922 had superior efficacy when compared to chemotherapy agents docetaxel or pemetrexed in patients whose tumor had EGFR mutations.
- Trial name
- NCT01646125
- Testing
- AUY922, Docetaxel, Pemetrexed
- Where
- 27 sites in United States, France and 10 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
This clinical trial studies combination chemotherapy, radiation therapy, and bevacizumab in treating patients with newly diagnosed stage III non-small cell lung cancer that cannot be removed by surgery.
- Conditions
- Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma
- Trial name
- NCT00334815
- Testing
- Bevacizumab, Cisplatin, Docetaxel
- Where
- 61 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.
Phase II study to determine progression free survival (PFS) of nab-paclitaxel administered in combination with gemcitabine, at two different dose combinations as first line therapy in patients with unresectable stage IIIB/stage…
- Trial name
- NCT02405910
- Testing
- Nab-paclitaxel, Gemcitabine
- Where
- United States
- Sponsor
- West Virginia University
Carcinoma, Non-Small-Cell Lung
Fruquintinib Combined With Sintilimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer
A phase II study to assess the efficacy and safety of Fruquintinib Combined With Sintilimab and Chemotherapy as a first-line treatment in patients with unresectable or metastatic advanced Wild-type Genotype non-squamous Non-small…
- Trial name
- NCT04956146
- Testing
- Fruquintinib，Sintilimab，Pemetrexed，Carboplatin
- Where
- China
- Volunteers
- 46 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Non Small Cell Lung Cancer
Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy
This is an open-label, randomized, non-comparative, multicentre, phase II study in which NSCLC patients who have progressed following chemotherapy and immunoptherapy are randomized to receive treatment with either paclitaxel and…
- Trial name
- ADAPTABLE (NCT05781308)
- Testing
- Paclitaxel, Bevacizumab, Atezolizumab
- Where
- 44 sites in France
- Volunteers
- 156 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Lung Cancer
Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor…
- Trial name
- NCT00217698
- Testing
- cisplatin, gefitinib, gemcitabine hydrochloride
- Where
- 14 sites in Switzerland
- Volunteers
- 63 people
- Sponsor
- Swiss Cancer Institute
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma
- Trial name
- NCT06799065
- Testing
- ATX-295, ATX-295 and bevacizumab (or biosimilar)
- Where
- 11 sites in United States
- Volunteers
- 218 people
- Sponsor
- Accent Therapeutics
Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers
A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors
This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of oral (PO) GDC-0941 administered in combination with PO erlotinib in patients with advanced solid…
- Trial name
- NCT00975182
- Testing
- GDC-0941, erlotinib HCl
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 58 people
- Sponsor
- Genentech, Inc.
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Non-Squamous Non-Small Cell Lung Cancer
A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.
This single arm study will evaluate the feasibility of treatment with 2 dose levels of Avastin in combination with concurrent thoracic radiation and chemotherapy in patients with locally advanced unresectable non-squamous…
- Trial name
- NCT00776698
- Testing
- bevacizumab [Avastin], cisplatin, etoposide
- Where
- 5 sites in Netherlands, United Kingdom
- Volunteers
- 1 people
- Sponsor
- Hoffmann-La Roche
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)
This phase II LUNG-MAP treatment trial studies how well combination treatment (talazoparib plus avelumab) works in treating patients with non-squamous non-small cell lung cancer that has an STK11 gene mutation and has come back…
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- NCT04173507
- Testing
- Avelumab, Talazoparib, Talazoparib Tosylate
- Where
- 325 sites in United States
- Volunteers
- 47 people
- Sponsor
- SWOG Cancer Research Network
Advanced/Metastatic Solid Tumors, Bladder Cancer
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas.
- Conditions
- Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer
- Trial name
- NCT07090499
- Testing
- PF-08046876, Pembrolizumab, Cisplatin
- Where
- 31 sites in United States, Canada and 4 more
- Volunteers
- 540 people
- Sponsor
- Pfizer
Advanced Solid Tumor, Lymphoma
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study.
- Conditions
- Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT04106167
- Testing
- Allogeneic natural killer (NK) cell
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fate Therapeutics
Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2.
- Conditions
- Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT04180371
- Testing
- BT5528, Nivolumab
- Where
- 28 sites in United States, Belgium and 3 more
- Volunteers
- 288 people
- Sponsor
- BicycleTx Limited